Home » ENROLLMENT BEGINS IN OMRIX'S THROMBIN STUDY
ENROLLMENT BEGINS IN OMRIX'S THROMBIN STUDY
Omrix Biopharmaceuticals has announced that patient enrollment in the multicenter, Phase III pivotal trial for the company's Thrombin stand-alone product candidate has been completed.
Omrix's Thrombin stand-alone, which is derived from human plasma, is designed to provide effective hemostasis (control of bleeding) without the risk of adverse reactions associated with the use of bovine-sourced hemostats. The drug will be available in a frozen liquid form making it ready for immediate use without the need for re-constitution. While the product will have a two-year stability, it can be stored liquid in the operating room refrigerator for 30 days.
KEYWORDS Drug Pipeline Alert